Contex

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The company focuses on developing small molecule and immunotherapy treatments for female-specific cancers, including breast, endometrial, and ovarian cancers. Its lead clinical candidate, onapristone extended release (ONA-XR), is a potent and selective progesterone receptor antagonist currently being evaluated in multiple Phase 2 trials. Additionally, Context is advancing CTIM-76, a bispecific antibody targeting Claudin 6 and CD3, designed to treat a variety of solid tumors. By targeting hormone-driven and tumor-specific pathways, Context aims to provide more effective and less toxic treatment options for patients with high unmet medical needs.